Shares of Pfizer Inc. (NYSE:PFE) [Trend Analysis] swings enthusiastically in regular trading session, it an raise of 0.59% to close at $34.14. OncoImmune Inc. reported that it inked an exclusive option and license contract with Pfizer Inc. (PFE) for ONC-392, a novel, differentiated preclinical anti-CTLA4 monoclonal antibody in a accord worth up to $250 million in upfront and potential milestone payments.
As per the terms of the contract, Pfizer plans to evaluate ONC-392 up until a certain agreed-upon time to determine whether it will exercise its option to exclusively license ONC-392 as well as any other OncoImmune anti-CTLA4 antibodies. If Pfizer exercises its option under the contract, Pfizer would be responsible for all development and potential commercialization of the program, and OncoImmune would be eligible to receive potential developmental and commercial milestone payments as well as royalties, tiered from mid-single up to low-double digits, on sales of any potential resulting products. Moving forward to saw long-term intention, the experts calculate Return on Investment of 7.30%. The stock is going forward its fifty-two week low with 22.95% and lagging behind from its 52-week high price with -7.93%. PFE last month stock price volatility remained 1.23%.
Viveve Medical, Inc. (NASDAQ:VIVE) [Trend Analysis] knocking active thrust in leading trading session, shares an raise of 10.05% to 7.01 with about 53219 shares have changed hands in this session. Viveve Medical, Inc. (NASDAQ:VIVE) reported that Brigitte Smith has reinked as a director of Viveve’s Board of Directors, comprising from her positions as Chairman of the Board and member of the Compensation Committee and Governance and Nominating Committee. Her resignation will be effective September 30, 2016.
“We thank Brigitte Smith for her expert counsel and guidance during her long tenure as a valued member of the board, which has played an important role in helping us advance our business strategy and our global commercial plans for the Viveve System,” stated Patricia Scheller, chief executive officer of Viveve. “We will miss her dedicated support for the Firm and wish her well with her future endeavors.” The stock is going forward its fifty-two week low with 74.38% and lagging behind from its 52-week high price with -33.24%.
Same, the positive performance for the quarter recorded as 40.57% and for the year was 3.09%, while the YTD performance remained at 3.70%. VIVE has Average True Range for 14 days of 0.76.
Cummins Inc. (NYSE:CMI) [Trend Analysis] retains strong position in active trade, as shares scoring 1.24% to $119.51 in a active trade session, while looking at the shares volume, about 1.01 Million shares have changed hands in this session. The firm has institutional ownership of 85.20%, while insider ownership included 0.20%. CMI attains analyst recommendation of 3.00 with week’s performance of -0.31%. Investors looking additional ahead will note that the Price to next year’s EPS is -2.35%.